Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania
about
Tuberculosis and hepatic steatosis are prevalent liver pathology findings among HIV-infected patients in South AfricaThe effect of tuberculosis treatment on virologic and CD4+ cell count response to combination antiretroviral therapy: a systematic reviewEffect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant womenKey toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship.Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populationsEvaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in ethiopian patients.Hepatic Enzyme Alterations in HIV Patients on Antiretroviral Therapy: A Case-Control Study in a Hospital Setting in GhanaPharmacogenomics Implications of Using Herbal Medicinal Plants on African Populations in Health TransitionGenome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity.Hematological and liver toxicity of anti-tuberculosis drugs.HLA-B*57 Allele Is Associated with Concomitant Anti-tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians.Genome-Wide Association and Replication Study of Hepatotoxicity Induced by Antiretrovirals Alone or with Concomitant Anti-Tuberculosis Drugs.CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.Role of Cytochrome P450 2B6 Pharmacogenomics in Determining Efavirenz-Mediated Central Nervous System Toxicity, Treatment Outcomes, and Dosage Adjustments in Patients with Human Immunodeficiency Virus Infection.Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation.Changing clinical profile and factors associated with liver enzyme abnormalities among HIV-infected persons.A clinicopathological cohort study of liver pathology in 301 patients with human immunodeficiency virus/acquired immune deficiency syndrome.Liver transplantation for acute liver failure due to efavirenz hepatotoxicity: the importance of routine monitoring.Effects of Khat (Catha edulis) use on catalytic activities of major drug-metabolizing cytochrome P450 enzymes and implication of pharmacogenetic variationsLong-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype
P2860
Q28543376-CD5E809B-9AAF-4E9B-AA0C-0CBA5C6B6B7EQ30658709-6F24C283-89BE-43AB-A040-F0E6EA2647FFQ33869119-6C9E4D72-2503-430A-AE47-24ED4535BF11Q34536677-46E9EBA0-7912-429D-9DE0-8F166E2C7D76Q34710641-D846A730-0D5B-4B64-83D2-8BCE645FE695Q34826590-F4D1B944-58DC-469F-8E5E-117B40D2A00BQ35142786-FF1E93D3-E065-4A83-9DAE-02724DCE6813Q35738818-E16E0B8B-9357-4F33-9627-5B5F9E5134A7Q36105822-395EDB6C-FC2F-4245-94E4-560C0EA14264Q36145491-8669F012-1514-4DC2-B9BC-3D14EE4CE890Q37358208-15DE9A63-D6D1-4482-89D3-DC4D731C2DACQ37667333-26F45E7B-5313-4F1F-BECC-258F71E06805Q38733565-D99994F5-E34D-461B-8521-2937B8E5C1FFQ38855121-350BB03F-134F-4821-BA7B-904C43FEF4DCQ38861140-24197DAB-4B5A-4E51-8126-2C7E8A52DF9BQ38990321-705A8186-512B-431E-96FA-E9FC2DA72C88Q39039468-44425F0F-8276-4DA0-97CF-8018516F8FF1Q39158128-0A3B677B-3D31-463E-8AD9-782BDBF13315Q40637208-DF7AE0C6-99BE-4669-B427-1B26CFF262D3Q41490253-0DB4D481-C4FD-4653-9B96-6C89212CED3AQ42274837-DA6BB503-AEB1-4121-9244-227F961EFCD2Q58003058-9E052020-9184-4349-BB73-6F984D7BF766Q58612379-1B4AC5C3-F3D8-4DF8-B720-D6B25BE3D49A
P2860
Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Liver enzyme abnormalities and ...... losis co-infection in Tanzania
@ast
Liver enzyme abnormalities and ...... losis co-infection in Tanzania
@en
Liver enzyme abnormalities and ...... losis co-infection in Tanzania
@nl
type
label
Liver enzyme abnormalities and ...... losis co-infection in Tanzania
@ast
Liver enzyme abnormalities and ...... losis co-infection in Tanzania
@en
Liver enzyme abnormalities and ...... losis co-infection in Tanzania
@nl
prefLabel
Liver enzyme abnormalities and ...... losis co-infection in Tanzania
@ast
Liver enzyme abnormalities and ...... losis co-infection in Tanzania
@en
Liver enzyme abnormalities and ...... losis co-infection in Tanzania
@nl
P2093
P2860
P921
P3181
P1433
P1476
Liver enzyme abnormalities and ...... losis co-infection in Tanzania
@en
P2093
Eliford Ngaimisi
Eric Sandstrom
Ferdinand Mugusi
Klaus-Dieter Riedel
Lars Lindquist
Mohamed Janabi
Muhammad Bakari
Omary Minzi
Sabina Mugusi
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0040180
P407
P577
2012-07-11T00:00:00Z